Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Two PEG-rhGH Preparations in Healthy Chinese Males
NCT06135155Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of peg-somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area under the concentration-time curve from time zero to infinity and 1 more. Started Nov 2023; status: completed.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06135155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135155.